22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          PTENP1 is a pseudogene of the PTEN tumor suppression gene (TSG). The functions of PTENP1 in clear-cell renal cell carcinoma (ccRCC) have not yet been studied. We found that PTENP1 is downregulated in ccRCC tissues and cells due to methylation. PTENP1 and PTEN are direct targets of miRNA miR21 and their expression is suppressed by miR21 in ccRCC cell lines. miR21 expression promotes ccRCC cell proliferation, migration, invasion in vitro, and tumor growth and metastasis in vivo. Overexpression of PTENP1 in cells expressing miR21 reduces cell proliferation, invasion, tumor growth, and metastasis, recapitulating the phenotypes induced by PTEN expression. Overexpression of PTENP1 in ccRCC cells sensitizes these cells to cisplatin and gemcitabine treatments in vitro and in vivo. In clinical samples, the expression of PTENP1 and PTEN is correlated, and both expressions are inversely correlated with miR21 expression. Patients with ccRCC with no PTENP1 expression have a lower survival rate. These results suggest that PTENP1 functions as a competing endogenous RNA (ceRNA) in ccRCC to suppress cancer progression.

          Related collections

          Author and article information

          Journal
          Mol. Cancer Ther.
          Molecular cancer therapeutics
          1538-8514
          1535-7163
          Dec 2014
          : 13
          : 12
          Affiliations
          [1 ] Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
          [2 ] The Wistar Institute, Philadelphia, Pennsylvania.
          [3 ] Department of Urology and Helen-Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
          [4 ] The Wistar Institute, Philadelphia, Pennsylvania. xuhua@mail.hust.edu.cn qhuang@wistar.org.
          [5 ] Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. xuhua@mail.hust.edu.cn qhuang@wistar.org.
          Article
          1535-7163.MCT-14-0245 NIHMS646860
          10.1158/1535-7163.MCT-14-0245
          4265235
          25249556
          08343fd3-d3a5-4af9-8626-fa7dd7d9a7f4
          ©2014 American Association for Cancer Research.
          History

          Comments

          Comment on this article